![]() Preventing COVID-19 among children is an important part of slowing the spread of severe acute respiratory syndrome coronavirus 2 and protecting them from severe illness and adverse outcomes, including long-term effects from their initial infection. The wide availability of vaccines, the rapid development and deployment of COVID-19 diagnostic tests authorized by the US Food and Drug Administration 1 (including 235 molecular, 88 antibody, and 34 antigen, or rapid), and evidence-based refinement of safety guidance aimed to lower COVID-19 community transmission rates and facilitate a safe return to everyday activities, including in-person learning. Finally, in June 2022, the age of authorization for COVID-19 vaccination included children as young as 6 months of age. In October 2021, this was amended again allowing the vaccination for children 5 through 11 years of age. In May 2021, the US Food and Drug Administration amended the Emergency Use Authorization for COVID-19 vaccination to include adolescents 12 through 15 years of age. Another key milestone was the development of vaccines for COVID-19. Indeed, by the 2021 to 2022 academic year, most schools had opened their doors for in-person learning with various mitigation strategies available to prevent COVID-19 transmission, including masking, distancing, and quarantining. ![]() For many communities, children who engaged in remote instruction for >1 year regained access to traditional learning environments, opportunities for social and emotional development, consistent nutrition, and regular physical activity. Throughout the coronavirus disease 2019 (COVID-19) pandemic, communities marked crucial milestones that signaled a return to “normal.” One of the most pivotal was the safe return of children to in-person school settings. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |